- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03337737
The Effects of 10 Days of Extreme Endurance on Performance (ExtremeEnd)
The Effects of 10 Days of Extreme Endurance on Performance, Buffering Capacity During Exercise and Post Exercise Muscle Damage, Oxidative Stress and Inflammation
The study will be a double blind, placebo controlled cross over design with equal treatment and washout periods. Participants will sign an informed consent document prior to data collection and will provide descriptive information about their physical activity by filling out the Leisure and Physical Activity Survey. The participants will be 12 healthy, active college aged males. The participant will have height and weight determined via a triple beam balance with stadiometer, and their body fat% determine via a Bod Pod Gold Standard system.
After wards the participants will supplement with either Placebo or Extreme Endurance (random assignment for order) for ten days. The first 4 days will the participants will ingest four tablets in the morning and evening (8 tablets total) followed by 6 days of three tablets in the morning and evening (6 tablets total). Following the supplementation period the participant will report to the human performance lab where they will be fitted with a mask to collect expired gases and will perform a 25 watt ramp protocol on an electronically braked cycle ergometer. During this test the participant will have a short warm up period, and then a computer will automatically adjust the workload on the bike such that a slope of 25 watts/min is achieved. The test will conclude when the subject reaches volitional exhaustion. Expired gases will be assessed with a COSMED QUARK CPET system. Prior to, and every two minutes during the exercise lactate will be assessed via dermal puncture and a handheld monitor. Ten minutes after the cessation of exercise, a venipuncture will be performed in the antecubetal space and blood will be collected into a serum separator tube. This blood will be spun down in a clinical centrifuge and the serum drawn off and ammonia determined via enzymatic reaction. The remaining serum will be aliquoted and stored at -80 degrees Celsius for later analysis (muscle damage, oxidative stress, inflammation). Participants will then have a ten day rest period after which they will begin the 10 day supplementation period and exercise trial with the opposite supplement.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Background and Purpose:
Extreme Endurance has been studied in Europe and the data from these studies suggested that the supplement may reduce acidity and increase exercise performance. The purpose of the present investigation is to assess the total effects of Extreme Endurance during exercise. The investigation will assess the following:
Performance:
Performance will be measured as the peak wattage achieved at the lactate, and ventilator thresholds as well as the peak wattage attained during a 25 watt ramp protocol on a electronically braked cycle ergometer. During this test expired gases will be assessed breath by breath, and lactate will be measured every 2 minutes.
Buffering Capacity:
In the human body decreased inter-muscular pH can be quantified through changes in the amount of expired CO2 and increases in serum ammonia (highly correlated with changes in pH associated with high intensity exercise) and lactate measured in whole blood during the exercise.
Muscle Damage:
Post exercise stress and damage to muscle tissue can be quantified by examining the blood for substances normally contained in the muscle tissue only. For this study both creatine kinase and lactate dehydrogenase will be assessed, both have been used as markers of muscle damage in a plethora of scientific publications.
Oxidative Stress:
During exercise free radicals are generated, which a supplement such as Extreme Endurance can potentially reduce. For this study 8OHdG will be measured, this is a marker of oxidative damage to DNA caused by free radicals produced during exercise.
Inflammation:
Exercise produces a well documented inflammatory response. To examine the effects of Extreme Endurance on inflammation a custom multiplex assay will be run that will measure IL-2, IL-6, TNF alpha and C-reactive protein. These are all common markers for inflammation.
Research Questions:
- Does Extreme Endurance improve performance and increase power output during a graded cycling protocol compared to placebo?
- Does Extreme Endurance improve buffering capacity during a graded cycling protocol compared to placebo?
- Does Extreme Endurance reduce muscle damage caused by a graded cycling protocol compared to placebo?
- Does Extreme Endurance reduce oxidative stress caused by a graded cycling protocol compared to placebo?
- Does Extreme Endurance reduce inflammation caused by a graded cycling protocol compared to placebo?
Methodology
Study Design
The study will be a double blind, placebo controlled cross over design with equal treatment and washout periods. Participants will sign an informed consent document prior to data collection and will provide descriptive information about physical activity history by filling out the Leisure and Physical Activity Survey. The participants will be 16 healthy, active college aged males. The participants will have height and weight determined via a triple beam balance with stadiometer, and body fat% determine via a Bod Pod Gold Standard system.
After wards the participants will supplement with either Placebo or Extreme Endurance (random assignment for order) for ten days. The first 4 days will the participants will ingest four tablets in the morning and evening (8 tablets total) followed by 6 days of three tablets in the morning and evening (6 tablets total). Following the supplementation period the participants will report to the human performance lab where a mask will be fitted to collect expired gases and will perform a 25 watt ramp protocol on an electronically braked cycle ergometer. During this test the participant will have a short warm up period, and then a computer will automatically adjust the workload on the bike such that a slope of 25 watts/min is achieved. The test will conclude when the participant reaches volitional exhaustion. Expired gases will be assessed with a COSMED QUARK CPET system. Prior to, and every two minutes during the exercise lactate will be assessed via dermal puncture and a handheld monitor. Ten minutes after the cessation of exercise, a venipuncture will be performed in the antecubetal space and blood will be collected into a serum separator tube. This blood will be spun down in a clinical centrifuge and the serum drawn off and ammonia determined via enzymatic reaction. The remaining serum will be aliquoted and stored at -80 degrees Celsius for later analysis (muscle damage, oxidative stress, inflammation). Participants will then have a ten day rest period after which they will begin the 10 day supplementation period and exercise trial with the opposite supplement.
Immunoassays
At the conclusion of data collection, serum aliquots will be thawed and analyzed via colormetric or chemiluminescent immunoassays.
Timeframe
Mar 2016 - Begin Subject Recruitment
Sept 2016 - Finish Data collection
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Able to participate in vigorous exercise
Exclusion Criteria:
- Any exercise contraindication
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Komparátor placeba: Placebo
Placebo will be composed of microcrystalline cellulose in a gel capsule
|
|
|
Aktivní komparátor: Extreme Endurance
Dietary Supplement manufactured by LifeSpan International LLC
|
Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Human Performance
Časové okno: 10 days
|
Treadmill Exercise
|
10 days
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Oxidative Stress
Časové okno: 10 days
|
8OHdG assessment
|
10 days
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- FWA00000758
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Lidský výkon
-
Jinling Hospital, ChinaNeznámýCrohnova nemoc | Methylace | Illumina Human Methylation 850k BeadChipČína
-
Merck Sharp & Dohme LLCDokončenoUroteliální karcinom Associated 1 RNA, Human
-
KTO Karatay UniversityNáborHPV (Human Papillomavirus) - asociovanýTurecko (Türkiye)
-
Ufuk UniversityNáborStav imunizace proti HPV | HPV (Human Papillomavirus) - asociovanýTurecko (Türkiye)
-
Paul W. Read, MDUkončenoOrofaryngeální spinocelulární karcinom (OPSCCA) | HPV (Human Papillomavirus) - asociovanýSpojené státy
-
Second Affiliated Hospital, School of Medicine,...First People's Hospital of Hangzhou; Women's Hospital School Of Medicine Zhejiang... a další spolupracovníciZatím nenabírámeFotodynamická terapie (PDT) | HPV (Human Papillomavirus) - asociovaný | CIN 2 | Hsil, vysoce kvalitní spinocelus intraepiteliální lézeČína
-
M.D. Anderson Cancer CenterZatím nenabírámeHPV (Human Papillomavirus) - asociovanýSpojené státy
-
Vastra Gotaland RegionNáborMyelodysplastický syndrom | Akutní myeloidní leukémie | Difuzní velký B buněčný lymfom (DLBCL) | HPV (Human Papillomavirus) - asociovaný | Příjemci transplantace alogenních kmenových buněkŠvédsko
-
QurasenseNáborScreening rakoviny děložního čípku | HPV infekce | HPV | HPV infekce | Screeningový test | HPV DNA | Infekce HPV 16 | HPV (Human Papillomavirus) - asociovaný | Rakovina děložního čípku Cin Grade | Vysoce rizikové HPV | Rakovina děložního čípku (Včasná detekce)Spojené státy
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbDokončenoStádium IVA spinocelulárního karcinomu ústní dutiny | Stádium IV hypofaryngeálního spinocelulárního karcinomu | Stádium IVA laryngeálního spinocelulárního karcinomu | Fáze IVA orofaryngeálního spinocelulárního karcinomu | Stádium IVB Laryngeální spinocelulární karcinom | Stádium IVB orofaryngeální... a další podmínkySpojené státy